Biocryst Pharmaceuticals (BCRX) EBIT Margin (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) reported EBIT Margin of 448.55% for Q1 2026, down 46314.0% on a YoY basis from N/an in Q1 2025, and down 101.22% quarter-over-quarter from 36777.54% in Q4 2025.
Biocryst Pharmaceuticals (BCRX) EBIT Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals has reported EBIT Margin for 17 years, with the latest figure at 448.55% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 46314.0% year-over-year to 448.55%; the trailing twelve-month figure through Mar 2026 stood at 79.57% (down 8616.0% YoY), and the FY2025 full-year result was 38.98%, up 3954.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 448.55%, down from 36777.54% in the prior quarter.
- The five-year high for EBIT Margin was 36777.54% in Q4 2025, with the low at 448.55% in Q1 2026.
- Historically, EBIT Margin has averaged 2118.58% across 5 years, with a median of 15.62% in 2024.
- Annual changes were most pronounced in 2025 — EBIT Margin soared 3678097 bps — and 2026, when it sank 46314 bps.
- Biocryst Pharmaceuticals' EBIT Margin stood at 58.22% in 2022, then climbed by 22 bps to 45.68% in 2023, then soared by 92 bps to 3.43% in 2024, then jumped by 1073192 bps to 36777.54% in 2025, then tumbled by 101 bps to 448.55% in 2026.
- The last three EBIT Margin figures came in at 448.55% (Q1 2026), 36777.54% (Q4 2025), and 18.56% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 20.77% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 23.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -122.23% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -12.88% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Biocryst Pharmaceuticals | 2.02 Bn | 1.78 Bn | 151.04 Mn | -448.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -448.55% |
| Dec 31, 2025 | 36,777.54% |
| Sep 30, 2025 | 18.56% |
| Jun 30, 2025 | 18.23% |
| Mar 31, 2025 | 14.59% |
| Dec 31, 2024 | -3.43% |
| Sep 30, 2024 | 6.57% |
| Jun 30, 2024 | 8.01% |
| Mar 31, 2024 | -15.62% |
| Dec 31, 2023 | -45.68% |
| Sep 30, 2023 | -13.74% |
| Jun 30, 2023 | -25.10% |
| Mar 31, 2023 | -41.31% |
| Dec 31, 2022 | -58.22% |
| Sep 30, 2022 | -23.01% |
| Jun 30, 2022 | -52.98% |
| Mar 31, 2022 | -100.07% |
| Dec 31, 2021 | -110.64% |
| Sep 30, 2021 | -108.76% |
| Jun 30, 2021 | -59.21% |